In 2025, Philips saw 6% order intake growth and EUR 17.8 billion in sales, with an 80 basis points increase in EBITA margin. CEO Roy Jakobs highlighted strong performance and innovation in healthcare. Q4 comparable order intake grew 7%, with a 15.1% EBITA margin increase. Full-year free cash flow reached EUR 1,200 million.

Philips unveiled a plan for profitable growth with new 2030 Impact Ambitions, targeting mid-single-digit sales growth and mid-teens EBITA margin by 2028. The company emphasized segment-specific strategies, innovation, and disciplined execution. CEO Roy Jakobs praised the team’s commitment to driving sustainable impact for patients and health systems.

Q4 showed a 7% growth in comparable order intake and sales across all segments. EBITA margin increased by 160 basis points to 15.1%, driven by innovation and productivity. Full-year figures included a 6% order intake growth and a 2% sales increase, with an 80 basis points EBITA margin growth to 12.3%.

Diagnosis & Treatment saw 4% sales growth in Q4, with an 11.8% EBITA margin. Connected Care had a 7% sales increase and a 16.5% EBITA margin. Personal Health experienced a 14% sales growth, with a 23.0% EBITA margin in Q4.

Philips showcased world-first innovations at RSNA, including a helium-free 3.0T MR magnet and a detector-based Spectral CT powered by AI. The acquisition of SpectraWAVE and partnerships with AdventHealth and US private healthcare providers further strengthened Philips’ presence in the industry. The company was also recognized as a top global innovator for the 13th consecutive year. Philips has completed a successful three-year, EUR 2.5 billion productivity program, saving EUR 0.8 billion in 2025. For 2026, Philips expects 3%-4.5% sales growth, 12.5%-13.0% adjusted EBITA margin, and EUR 1.3-1.5 billion in free cash flow. They plan to propose a dividend of EUR 0.85 per common share at the 2026 AGM.

Philips will present a plan for profitable growth at their Capital Markets Day, focusing on segment-specific strategies, innovation as a key driver, and disciplined execution. Their mid-term targets for 2026-2028 include mid-single-digit sales growth, mid-teens adjusted EBITA margin, and EUR 4.5-5.0 billion in free cash flow.

Philips launches its 2030 Impact Ambitions, integrating ESG commitments into their growth plan. The ambitions focus on improving health, reducing environmental impact, and strong governance. Investors can join a conference call and webcast to discuss Philips’ results and future plans. The company aims to deliver sustainable value through impactful innovation. Philips faces risks and uncertainties due to factors like macro-economic changes, geopolitical tensions, and tariffs. The company must adapt to the evolving health technology landscape and focus on AI and informatics leadership. Challenges include integrating acquisitions, ensuring product quality, and cybersecurity. Philips’ future results may vary from forward-looking statements.

Market share data in this document is based on outside sources and management estimates. Philips uses non-IFRS financial measures to discuss its financial position, which should be viewed alongside IFRS measures. Inside information is disclosed in accordance with the EU Market Abuse Regulation. Financial reporting is in euros and amounts may not add up precisely due to rounding.

Uncertain tax liabilities were reclassified from non-current to current income tax liabilities as of September 30, 2025. Per share calculations have been adjusted to reflect share issuances in 2025 for the 2024 share dividend. Non-IFRS financial measures are used, and further information can be found in the Annual Report 2024.

Read more at GlobeNewswire.: Philips delivers full year 2025 with growth acceleration,